Pazopanib HCl (GW786034 HCl)

Catalog No.S1035

Pazopanib HCl (GW786034 HCl) Chemical Structure

Molecular Weight(MW): 473.98

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • IC50 of Pazopanib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. (B): VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined at indicated times in the presence or absence of Pazopanib.

    J Virol, 2011, 85(5): 2296-303. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

    MRC5 non-transformed human lung fibroblasts were infected with influenza viruses (100 multiplicity of infection). Two hours after infection the cells were treated with vehicle control; sorafenib tosylate (2mM); pazopanib (2mM); OSU-03012 (2mM); and AR-13 (2mM). Twenty-four hours after infection the cells are treated with live/dead agent where green cells are viable and cells staining yellow or red are considered dead. Cells are examined at 10 magnification in a Hermes wide-field microscope (n¼3 SEM) P<0.05 less than vehicle control level of virus-mediated cell killing.

    J Cell Physiol, 2016, 231(10):2286-302.. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

  • Effect of HDIL-2/TKI on apoptosis of RCC cells. Three RCC cell lines treated with different concentrations of Pazopanib and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Features A multi-kinase inhibitor.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
FGFR [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] Pazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HUVEC M1TPe2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXnpcohq[mm2czD0bIUhXkWJRj3pcoR2[2WmIIDyc4xq\mW{YYTpc44hd2ZiSGXWSWN{ NVzNc|d{OTh4MkCzPFI>
HUVEC MoOzT4lv[XOnIHHzd4F6 NEL6dJZqdmirYnn0d{BXTUeILXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIG\FS2ZTNTJiaX6gTHVXTUNiY3XscJMhf2m2aDDhckBKSzVyIH;mJQKJxDhibl2= MlvLNVg3OjB|OEK=
MM MkHsT4lv[XOnIHHzd4F6 MXzpcohq[mm2czDWSWdHNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKG[udEG= MYWxO|E3PDN|Mh?=
MM.1S Mo\oS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1vHNFExKM7:Zz;tUC=> MYTpcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? MVOxO|E3PDN|Mh?=
MM.1R NF;VUIJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2DTXVExKM7:Zz;tUC=> MXzpcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? Mnj0NVcyPjR|M{K=
RPMI MoDuS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1PWR|ExKM7:Zz;tUC=> M33mWIlvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq NHLGc2YyPzF4NEOzNi=>
Dox40 M2C1V2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkjQNVAh|rypL33M M2XSPIlvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq NVP3OJhsOTdzNkSzN|I>
INA-6 MnTZS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmjJNVAh|rypL33M NEfFc21qdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?= NVyze|VTOTdzNkSzN|I>
OPM2 NV\VdWcyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MlfKNVAh|rypL33M NGflbnVqdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?= MVKxO|E3PDN|Mh?=
U266 NU\GR|dWT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MmnBNVAh|rypL33M MUfpcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? M3fkVVE4OTZ2M{Oy
MM.1S NHKzdXJkgXSxdH;4bYNqfHliYYPzZZk> MmO5NlAh|rypL33M M1PrPIlvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= MYSxO|E3PDN|Mh?=
MM.1R NWnQe2Fn[3m2b4TvfIlkcXS7IHHzd4F6 M1jzcFIxKM7:Zz;tUC=> MV\pcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu MkDiNVcyPjR|M{K=
RPMI NXHXeG1W[3m2b4TvfIlkcXS7IHHzd4F6 NUjUWGt1OjBizsznM41N NUjDSXVzcW6qaXLpeJMhVU1iQ3XscEBUfXK4aY\hcC=> NH3OdoMyPzF4NEOzNi=>
Dox40 NWjVbHU{[3m2b4TvfIlkcXS7IHHzd4F6 NVXJNppNOjBizsznM41N MVfpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu NWjjRpduOTdzNkSzN|I>
INA-6 MVnjfZRwfG:6aXPpeJkh[XO|YYm= MXyyNEDPxGdxbVy= NIHrTVNqdmirYnn0d{BOVSCFZXzsJHN2en[rdnHs NF3NfI8yPzF4NEOzNi=>
OPM2 NHXOXlNkgXSxdH;4bYNqfHliYYPzZZk> NWLzN3ltOjBizsznM41N NHXDR|FqdmirYnn0d{BOVSCFZXzsJHN2en[rdnHs MUKxO|E3PDN|Mh?=
U266 NIHXeHBkgXSxdH;4bYNqfHliYYPzZZk> NGPUdm8zOCEQvHevcWw> M{PkbolvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= NFT0O2UyPzF4NEOzNi=>
MM.1S NFi1eJFHfW6ldHnvckBie3OjeR?= Ml3Vd5VxeHKnc4Pld{BXTUeILVnu[JVk\WRiRX7kc5Rp\WyrYXygR4VtdCCScn;sbYZmemG2aX;uJIFv\CCPaXfyZZRqd25w MX2xO|E3PDN|Mh?=
MM.1R M3HkW2Z2dmO2aX;uJIF{e2G7 MnvZd5VxeHKnc4Pld{BXTUeILVnu[JVk\WRiRX7kc5Rp\WyrYXygR4VtdCCScn;sbYZmemG2aX;uJIFv\CCPaXfyZZRqd25w NUXxWXZ[OTdzNkSzN|I>
Dox40 Mlv5SpVv[3Srb36gZZN{[Xl? M2XC[5N2eHC{ZYPz[ZMhXkWJRj3JcoR2[2WmIFXu[I91cGWuaXHsJGNmdGxiUILvcIln\XKjdHnvckBidmRiTXnndoF1cW:wLh?= NG\hTJAyPzF4NEOzNi=>
OPM2 MlG0SpVv[3Srb36gZZN{[Xl? MVLzeZBxemW|c3XzJHZGT0ZvSX7keYNm\CCHbnTveIhmdGmjbDDD[YxtKFC{b3zp[oVz[XSrb36gZY5lKE2rZ4LheIlwdi5? MmmxNVcyPjR|M{K=
HBMEC MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGXtd45,OTBizszN M2TYZmROW09? NVe1dIRxUUN3ME2xJO69VQ>? NIqzT4wzOTB6MU[1Oi=>
HBMEC MU\GeY5kfGmxbjDhd5NigQ>? M3u1Vp4yKM7:TR?= MlHXSG1UVw>? NVO2UI45[WK{b3fheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[gWmVITlJ{IIfpeIgh\Gm|coXweIlwdiCxZjDkc5dve3S{ZXHtJHBNS87|MR?= NH\EcYUzOTB6MU[1Oi=>
HBMEC NXnMSVdZTnWwY4Tpc44h[XO|YYm= Mn7GglEh|ryP NVftbZoxTE2VTx?= MoLa[Il{enWydIOgeIhmKFKjcz3SZYYuTVKNIIDheIh4[XlidHjyc5VocCCmZXPy[YF{\WRicHjvd5Bpd3K7bHH0[YQhVUWNMT:yJIFv\CCHUluxM|I> MnTBNlExQDF4NU[=
HBMEC MUPGeY5kfGmxbjDhd5NigQ>? MX7+NlAh|ryP NH;iVZhFVVOR NYn6Z2tM\Gm|coXweJMhPTBnIH;mJJR2[mViZn;ycYF1cW:wIHH0JFEh|ryP NGrmcJUzOTB6MU[1Oi=>
MDA-MB-231 NFKwfpdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2H6dZ4yOCEQvF2= NF;rcY1FVVOR MVrJR|UxRTVizszN NV;0dZN3OjFyOEG2OVY>
MDA-MB-231 MUXGeY5kfGmxbjDhd5NigQ>? Mlz0NE42KM7:TR?= M4DWUGROW09? NHjUUmpqdmirYnn0d{B1cGViRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6 M4TVbFIyODhzNkW2
MDA-MB-231 MXTGeY5kfGmxbjDhd5NigQ>? NWG4copVPSEQvF2= MX3EUXNQ MUDpcoR2[2W|IHGgZ4VtdC2leXPs[UBienKnc4S= MXiyNVA5OTZ3Nh?=
J82 MXfjfZRwfG:6aXPpeJkh[XO|YYm= M{DXbp4yOCEQvF2= MmLlSG1UVw>? NXjkXnIyUUN3ME2yOE42PyEQvF2= NWDlPI05OjF3Mkm5NFA>
T24 MWrjfZRwfG:6aXPpeJkh[XO|YYm= MU\+NVAh|ryP NIPUSmlFVVOR MlW1TWM2OD13Mj60OUDPxE1? Ml3DNlE2Ojl7MEC=
HT1376 M{jnVYN6fG:2b4jpZ4l1gSCjc4PhfS=> MoPrglExKM7:TR?= NWHkRo1FTE2VTx?= MWPJR|UxRTJ6LkKxJO69VQ>? MnnENlE2Ojl7MEC=
RT4 NWLibm1D[3m2b4TvfIlkcXS7IHHzd4F6 M1r0Wp4yOCEQvF2= Ml7QSG1UVw>? M{HuZmlEPTB;NT6xOEDPxE1? NH3uW48zOTV{OUmwNC=>
CRL1749 M4HlXYN6fG:2b4jpZ4l1gSCjc4PhfS=> NGOwNG5,OTBizszN M3vyOmROW09? Mlz1TWM2OD1{Mj62PUDPxE1? NES0ZWUzOTV{OUmwNC=>
HTB9 M4[wb4N6fG:2b4jpZ4l1gSCjc4PhfS=> MXP+NVAh|ryP NUTrbXNETE2VTx?= NUfKVJhrUUN3ME2xNU45PCEQvF2= NVrHOYM3OjF3Mkm5NFA>
Sup Mmr3Z5l1d3SxeHnjbZR6KGG|c3H5 MXP+NVAh|ryP NIDuVYhFVVOR MV3JR|UxRTV|LkOyJO69VQ>? MX[yNVUzQTlyMB?=
HTB3 M{TMcoN6fG:2b4jpZ4l1gSCjc4PhfS=> M2jWOZ4yOCEQvF2= M134UmROW09? NGjmXo9KSzVyPUG0MlE3KM7:TR?= M3;v[lIyPTJ7OUCw
CEC NELZfZRHfW6ldHnvckBie3OjeR?= MVL+NVAh|rypL33M MlrNSG1UVw>? MVLkc5dvNXKnZ4XsZZRmeyCYRVfGJIxmfmWucx?= MoS3NlE3OjB6MkK=
RPE MVHGeY5kfGmxbjDhd5NigQ>? MYT+NVAh|rypL33M MYLEUXNQ MnHQ[I94di2{ZXf1cIF1\XNiVlXHSkBt\X[nbIO= MXmyNVYzODh{Mh?=
CEC MXTGeY5kfGmxbjDhd5NigQ>? Mm\TglUh|rypL33M NGnqXnlFVVOR NEC5fYhjdG:la4Og[Y5ld3SqZXzpZYwh[2WubDDtbYdz[XSrb36= M3zqdFIyPjJyOEKy
5637 M{\mPGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MWPEUXNQ NHfifI5KSzVyPUG1MlDjiIoQvF2= NWPkNppWOjN6OEe2NFU>
J82 MoHnS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYSzUFh1TE2VTx?= MlziTWM2OD1zOD605qCK|ryP NGrVZ4YzOzh6N{[wOS=>
5637 NIHhc2pCfXSxcHjh[5kh[XO|YYm= NELYc5UzOCEQvF2= MVXEUXNQ NGK1Zop1emmpZ3Xyd{B1cGViYYX0c5Bp[WerYzDwdo9k\XO| NIjvTXozOzh6N{[wOS=>
J82 MVTBeZRweGijZ4mgZZN{[Xl? M2fkOFIxKM7:TR?= NXyzSXJ4TE2VTx?= NEOzZ5d1emmpZ3Xyd{B1cGViYYX0c5Bp[WerYzDwdo9k\XO| NFrUVWozOzh6N{[wOS=>
5637 NHfHfpZHfW6ldHnvckBie3OjeR?= NYXWNWFqOjBizszN NF7RT41FVVOR NXX2PXBWcW6mdXPld{BtgXOxc3;tZYwu\GWyZX7k[Y51KG6nY4Lvd4l{ M3;2cFI{QDh5NkC1
J82 NVzSfoJMTnWwY4Tpc44h[XO|YYm= M17Nd|IxKM7:TR?= MULEUXNQ MX7pcoR2[2W|IHz5d49{d22jbD3k[ZBmdmSnboSgcoVkem:|aYO= MXWyN|g5PzZyNR?=
5637 NHXQNHdHfW6ldHnvckBie3OjeR?= MnPMNlAh|ryP M1jkV2ROW09? MUPpcoR2[2W|IHz5d49{d22nIHHseIVz[XSrb36gZY5lKGmwaHnibZR{KEOEIHHjeIl3cXS7 M3nvVFI{QDh5NkC1
J82 NHL6SGdHfW6ldHnvckBie3OjeR?= MnTpNlAh|ryP NIWxZohFVVOR NX;xW5JrcW6mdXPld{BtgXOxc3;t[UBidHSncnH0bY9vKGGwZDDpcohq[mm2czDDRkBi[3Srdnn0fS=> NYPUZ45VOjN6OEe2NFU>
KATO-II M4K3VWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmjWOUDPxE1? NVe3N21nTE2VTx?= MUjicI9kc3NicILvcIln\XKjdHnvci=> MlHuNlUzPDl3NUe=
OCUM-2M MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M121U|Uh|ryP MkjuSG1UVw>? M3rtSoJtd2OtczDwdo9tcW[ncnH0bY9v M2D3SlI2OjR7NUW3
SNU-16 NVm1bWx1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEHuRYg2KM7:TR?= M3zXbGROW09? Mmf1Zoxw[2u|IIDyc4xq\mW{YYTpc44> M1vN[FI2OjR7NUW3
HSC-39 MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NEXDTZc2KM7:TR?= NIDxcZlFVVOR MmDaZoxw[2u|IIDyc4xq\mW{YYTpc44> NX32eWVSOjV{NEm1OVc>
KATO-II MXjjfZRwfG:6aXPpeJkh[XO|YYm= MorzglExKM7:TR?= NHrnNmdFVVOR M4POWWlEPTB;MD6xJJRwKDJwMDFOwI1wdC:O M1rmfVI2OjR7NUW3
OCUM-2M NIjlVmdkgXSxdH;4bYNqfHliYYPzZZk> MU\+NVAh|ryP NX7QZnQ5TE2VTx?= M2H2N2lEPTB;MD6xJJRwKDJwMDFOwI1wdC:O NFXaUZozPTJ2OUW1Oy=>
SNU-16 NHOycnVkgXSxdH;4bYNqfHliYYPzZZk> MYf+NVAh|ryP NI\hRXdFVVOR NIDXb3hKSzVyPUCuNUB1dyB{LkCg{txud2xxTB?= M2nsR|I2OjR7NUW3
HSC-39 MnXWZ5l1d3SxeHnjbZR6KGG|c3H5 M1W0PZ4yOCEQvF2= MoWzSG1UVw>? M2e4PGlEPTB;MD6xJJRwKDJwMDFOwI1wdC:O M{nB[|I2OjR7NUW3
NIH 3T3 M2HnSGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NX7TcGZ[hjFyIN88US=> MorPSG1UVw>? NFS1NWJqdmirYnn0d{Bk\WyuIHfyc5d1cCCjbnSgZ49td267IH\vdo1ifGmxbh?= NV75bJN3OjV{NEm1OVc>
KATO-III MofHSpVv[3Srb36gZZN{[Xl? M{DYSlEh|ryP MlrNSG1UVw>? Mn3jbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dB?= MWGyOVI1QTV3Nx?=
OCUM-2M NFzqc41HfW6ldHnvckBie3OjeR?= NFjJ[IIyKM7:TR?= MofoSG1UVw>? NHT1c21qdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0 MXSyOVI1QTV3Nx?=
KATO-III MU\BdI9xfG:|aYOgZZN{[Xl? MWGxJO69VQ>? NX3ZNIdCTE2VTx?= NG\1OlRqdmS3Y3XzJIFxd3C2b4Ppdy=> NVr5UXdvOjV{NEm1OVc>
OCUM-2M MlmzRZBweHSxc3nzJIF{e2G7 NXrVSIJjOSEQvF2= M{Dpb2ROW09? NUWyS4FFcW6mdXPld{BieG:ydH;zbZM> M{ToflI2OjR7NUW3
KATO-III MoXZSpVv[3Srb36gZZN{[Xl? Mn3BNUDPxE1? NEjZdWFFVVOR NXrKSXc3cW6qaXLpeJMhTkeIUkKgdIhwe3Cqb4L5cIF1cW:wIHHu[EBld3ewc4Ty[YFuKHOrZ37hcIlv\yCvb3zlZ5Vt\XN? Mlu3NlUzPDl3NUe=

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase enzyme assays:

VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M HEPES, pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated Pazopanib in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs.
Cell Research:

[1]

+ Expand
  • Cell lines: HUVEC cells
  • Concentrations: 0-10 μM
  • Incubation Time: 1 hour
  • Method:

    Phosphorylation of VEGFR2 is assessed in HUVEC stimulated with VEGF. HUVEC are plated in type-I collagen-coated 10 cm plates in Clonetics EGM-MV medium at 1.0-1.5 × 106 cells/plate. After 24 hours, the confluent cells are serum starved overnight by replacing the growth medium with Clonetics EBM medium containing 0.1% BSA, 500 μg/mL hydrocortisone. Cells are treated with Pazopanib at various concentrations for 1 hour, followed by addition of 10 ng/mL VEGF or vehicle for 10 min. Cells are solubilized in lysis buffer. VEGFR2 is immunoprecipitated using antiflk-1 antibody and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting and detection with antiflk-1 or with antiphosphotyrosine (anti-P-tyr-biotin) antibody. The VEGFR2 phosphorylation level is quantified by densitometry and normalized to the total VEGFR2 level.


    (Only for Reference)
Animal Research:

[2]

+ Expand
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (35.86 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 473.98
Formula

C21H23N7O2S.HCl

CAS No. 635702-64-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01072214 Completed Macular Degeneration GlaxoSmithKline March 9 2010 Phase 1
NCT00866528 Completed Lung Cancer Non-Small Cell GlaxoSmithKline July 9 2009 Phase 1
NCT02795819 Active not recruiting Renal Cell Carcinoma|Soft Tissue Sarcoma|Metastatic Disease Virginia Commonwealth University|National Cancer Institute (NCI) July 8 2016 Phase 1
NCT02450136 Recruiting Refractory Solid Tumors Samsung Medical Center October 8 2015 Not Applicable
NCT02300545 Recruiting Sarcoma Soft Tissue|Soft Tissue Sarcoma Washington University School of Medicine April 8 2015 Phase 2
NCT01956669 Recruiting Solid Tumours Novartis Pharmaceuticals|Children''s Oncology Group|Novartis October 8 2014 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) supplier | purchase Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) cost | Pazopanib HCl (GW786034 HCl) manufacturer | order Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID